<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293943</url>
  </required_header>
  <id_info>
    <org_study_id>AFNET-B04-1</org_study_id>
    <nct_id>NCT00293943</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>A Randomized Trial to Investigate the Significance of Complete Versus Incomplete Electrical Isolation of Pulmonary Veins by Radiofrequency-induced Linear Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrial Fibrillation Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrial Fibrillation Network</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the significance of complete versus incomplete&#xD;
      electrical isolation of pulmonary veins by radiofrequency-induced linear lesions in patients&#xD;
      with paroxysmal atrial fibrillation.&#xD;
&#xD;
      The study hypothesis ist that the complete linear PV isolation ablation is superior to the&#xD;
      non-complete linear PV isolation on the outcome of patients with idiopathic drug-refractory&#xD;
      atrial fibrillation. As a second hypothesis in this adaptive study design, the&#xD;
      non-inferiority of the complete linear PV isolation strategy will be tested.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation can be cured by elimination of triggering events such as atrial&#xD;
      extrasystoles originating from the pulmonary veins (PV) by selective or linear radiofrequency&#xD;
      current applications.&#xD;
&#xD;
      Although electrical isolation can be demonstrated by a circumferential mapping catheter&#xD;
      positioned at the PV ostium, longterm effect of such EP-guided PV isolation procedures&#xD;
      achieve about 60-70% of stable sinus rhythm during follow-up even in experienced centers.&#xD;
      Re-investigation of symptomatic patients after initially electrically isolated PVs&#xD;
      demonstrated a substantial amount of PV reconduction which might explain the arrhythmia&#xD;
      recurrence.&#xD;
&#xD;
      Although it was demonstrated that linear lesions for PV isolation is superior to the&#xD;
      selective ablation approach, conflicting data exists on the necessity to achieve complete&#xD;
      linear lesions. The groups of Pappone et al and Oral et al both published a success rate of&#xD;
      more than 90% of patients in sinusrhythm irrespective of the line completeness, which both&#xD;
      groups estimated to be reached in only 30% of cases.&#xD;
&#xD;
      Several advantages and disadvantages could advocate for either the complete versus the&#xD;
      incomplete ablation strategy: Performing the complete EP-guided linear PV isolation strategy&#xD;
      might take longer (mean duration 4.5 hours vs about 2 hours) and could thereby potentially&#xD;
      result in a higher risk of procedure-associated complications (air embolism, thrombus&#xD;
      formation, perforation). In addition, three transseptal sheaths might increase the risk of&#xD;
      tamponade and might aggravate the ability to safely navigate catheters in the left atrium.&#xD;
      Certainly, the procedure costs are higher, since in addition to the 3D mapping system two&#xD;
      circular mapping catheters are mandatory to facilitate the lesion deployment and avoidance of&#xD;
      intra-PV ablation.&#xD;
&#xD;
      In addition, an ablation strategy that does not depend on complete line deployment may be&#xD;
      sufficient to achieve stable sinus rhythm. Although, additional linear lesions between the PV&#xD;
      isolation segments and towards the mitral annulus as proposed by several centers with&#xD;
      incomplete linear PV isolation approaches might not be necessary to achieve stable sinus&#xD;
      rhythm. Potential complications such as atrio-esophageal fistula formation could be avoided&#xD;
      if no additional lesions eg. along the LA roof would be necessary. Both the costs of the&#xD;
      additional material (transseptal sheaths, circular mapping catheters) and the shorter&#xD;
      procedure duration (about 2 hours) would be reduced. On the other hand, these costs would be&#xD;
      balanced by the reduced number of re-ablation, if incomplete PV isolation would indeed lead&#xD;
      to a higher AF recurrence rate.&#xD;
&#xD;
      Since no data exist on the time course of the deployed ablation lines. Do patients with&#xD;
      recurrences of AF always have PV reconduction ? Vice versa, it also remains unclear if all&#xD;
      patients with stable sinus rhythm do experience this effect based on longterm PV isolation.&#xD;
      To assess the significance of the time course of PV isolation, the proposed study protocol&#xD;
      consists therefore of an invasive re-evaluation of all primarily ablated pts scheduled after&#xD;
      3 months of follow-up regardless of arrhythmia recurrence to investigate PV conduction&#xD;
      properties.&#xD;
&#xD;
      Finally, patients with symptomatic AF who underwent intensified ECG monitoring indicate that&#xD;
      the standard clinical procedures (assessment of symptoms and surface ECG recordings at long&#xD;
      intervals) are not sufficient to detect recurrent AF. Therefore, daily ECG monitoring is&#xD;
      planned in this trial to detect asymptomatic episodes of AF.&#xD;
&#xD;
      The proposed study protocol aims to investigate in prospective, randomized fashion the&#xD;
      significance of complete versus incomplete PV isolation by RFC-induced linear lesions. The&#xD;
      ablation will be randomized to a linear encircling around the ipsilateral PVs with the&#xD;
      endpoint of complete PV isolation proven by two circumferential mapping catheters versus the&#xD;
      same ablation procedure which will be terminated instantaneously when total PV isolation&#xD;
      occurs, thereby allowing at least one conduction gap along the isolation line. An invasive&#xD;
      re-evaluation is scheduled after 3 months for all pts to assess longterm PV conduction&#xD;
      properties.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours</measure>
    <description>Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Time to first occurrence of any documented relapse of atrial fibrillation</measure>
    <description>- Time to first occurrence of any documented relapse of atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Number and total duration of documented AF episodes</measure>
    <description>- Number and total duration of documented AF episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Number of hospitalizations due to atrial fibrillation</measure>
    <description>- Number of hospitalizations due to atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Number of visits without hospitalization</measure>
    <description>- Number of visits without hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Number of &quot;serious adverse events of special interest&quot;</measure>
    <description>- Number of &quot;serious adverse events of special interest&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Procedure parameters (duration, fluoroscopy, number of radiofrequency applications)</measure>
    <description>- Procedure parameters (duration, fluoroscopy, number of radiofrequency applications)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Procedural costs (including the costs of re-ablation if AF recurrence occurs)</measure>
    <description>- Procedural costs (including the costs of re-ablation if AF recurrence occurs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Quality of life</measure>
    <description>- Quality of life</description>
  </secondary_outcome>
  <enrollment type="Actual">232</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic paroxysmal symptomatic atrial fibrillation refractory to antiarrhythmic&#xD;
             therapy&#xD;
&#xD;
          -  Age 50 - 85 years&#xD;
&#xD;
          -  Patient willing to participate in randomized trial and an invasive follow-up at month&#xD;
             3 (-6)&#xD;
&#xD;
          -  Structural normal heart&#xD;
&#xD;
          -  Patient willing and able to participate in 12 months follow-up period&#xD;
&#xD;
          -  ECG documentation of atrial fibrillation (ECG, Holter, event recorders, etc) for at&#xD;
             least one AF event in the prior year (related to symptomatic or asymptomatic episodes)&#xD;
             with an average number of one episode per month&#xD;
&#xD;
          -  Written informed consent of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had previous pulmonary vein ablation procedures Patients with atrial&#xD;
             fibrillation secondary to a reversible cause&#xD;
&#xD;
          -  Known presence of intracardiac or other thrombi&#xD;
&#xD;
          -  Evidence of obstructive lung disease requiring bronchodilator therapy&#xD;
&#xD;
          -  Pregnant females or those of child bearing potential who have not had a negative&#xD;
             pregnancy test within 48 hours before treatment.&#xD;
&#xD;
          -  Other medical illness (i.e. cancer, congestive heart failure) that may cause the&#xD;
             patient to be non-compliant with the protocol, confound the data interpretation or is&#xD;
             associated with limited life-expectancy (i.e., less than one year)&#xD;
&#xD;
          -  History of bleeding diathesis or suspected pro-coagulant state contraindication to&#xD;
             anticoagulation therapy&#xD;
&#xD;
          -  Hyperthyroidism or hypothyroidism manifested clinically and in laboratory tests (TSH,&#xD;
             T3, T4)&#xD;
&#xD;
          -  Participation in a clinical trial within the last 30 days. Simultaneous participation&#xD;
             in a registry (e.g. project AB1 of the AFNET) is permitted.&#xD;
&#xD;
          -  Drug addiction or chronic alcohol abuse&#xD;
&#xD;
          -  Legal incapacity, or other circumstances which would prevent the patient from&#xD;
             understanding the aim, nature or extent of the clinical trial&#xD;
&#xD;
          -  Evidence of an uncooperative attitude&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G체nter Breithardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of M체nster</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl-Heinz Kuck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital St. Georg, Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Willems, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit채tsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital St. Georg, Department of Cardiology</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cardiac Center</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Cardiology</name>
      <address>
        <city>M체nster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-vorhofflimmern.de</url>
    <description>Homepage of the German Atrial Fibrillation Network</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>February 17, 2006</study_first_submitted>
  <study_first_submitted_qc>February 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2006</study_first_posted>
  <last_update_submitted>September 7, 2012</last_update_submitted>
  <last_update_submitted_qc>September 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Pulmonary vein ablation</keyword>
  <keyword>Linear lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

